Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma.

@article{Richardson2013PreclinicalDA,
  title={Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma.},
  author={Paul G Richardson and Constantine Mitsiades and Jacob P Laubach and Roman Hajek and Ivan {\vS}pi{\vc}ka and Meletios Athanasios Dimopoulos and Philippe Moreau and D S Siegel and Sundar Jagannath and Kenneth C. Anderson},
  journal={Leukemia research},
  year={2013},
  volume={37 7},
  pages={829-37}
}
Histone deacetylases (HDACs) mediate protein acetylation states, which in turn regulate normal cellular processes often dysregulated in cancer. These observations led to the development of HDAC inhibitors that target tumors through multiple effects on protein acetylation. Clinical evidence demonstrates that treatment with HDAC inhibitors (such as vorinostat, panobinostat, and romidepsin) in combination with other antimyeloma agents (such as proteasome inhibitors and immunomodulatory drugs) has… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
27 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

Similar Papers

Loading similar papers…